CPhI Aims for Russia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Aims for Russia


In 2011, the organisers of CPhI, UMB Live, announced their intention to explore the US via the launch of ICSE USA. This year, the organisers are once again setting their sights on new territory, this time in Russia.

CPhI Russia is due to take place in Russia’s St Petersburg at the Manege Central Exhibition Hall on 10–11 April 2013, alongside the IPhEB event, which is a key event in Russia for the pharmaceutical, biotechnological and medical industry. In a statement, UBM Live said that it had actively sought a partnership with RESTEC, the organiser of IPhEB, to facilitate access to the Russian market.

“The Russian pharmaceutical market is set for tremendous growth: this year we already have seen leading pharmaceutical companies, such as Novartis and AstraZeneca, opening manufacturing sites and R&D centres in the St. Petersburg region and other parts of Russia. We believe our industry leading face-to-face events and digital products can play a critical role in accelerating that growth and driving innovation in the Russian pharmaceutical market," Andrew Pert, brand director for CPhI Russia, said in a statement.

According to a survey conducted by UBM Live of visitors to CPhI Worldwide 2011, held in Frankfurt, 42% of attendees were already active in the Russian pharmaceutical market. More than one third also had plans to enter the market during the next two years.

Russia is currently the eleventh largest pharmaceutical market in the world and is projected to reach a value of $26.7 billion by the end of 2013.

You can find out more about CPhI Russia and register your interest here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here